Dorothy Whelan Quoted in Law360 Article, “Biologic Fights Drive PTAB Drug Challenges To Record High”
February 8, 2018
Dorothy Whelan, Principal and Post-Grant Practice Co-Chair was quoted in Law360’s article, “Biologic Fights Drive PTAB Drug Challenges To Record High” on February 8, 2018.
“When you look at the filers, a lot of them remain generic drug manufacturers,” said Dorothy Whelan, a principal at Fish & Richardson and one of the contributors to the report. “There’s another group that’s smaller but growing, and that’s in the biosimilars area.”
To view the full article please click here.
Click here to access Fish’s 2017 Post-Grant Report.